ATG16L1 Protein
Overview
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">ATG16L1 Protein</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>ATG16L1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>ATG16L1</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=ATG16L1" target="_blank">Search UniProt</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/autoimmune" style="color:#ef9a9a">Autoimmune</a>, <a href="/wiki/bacterial-infection" style="color:#ef9a9a">Bacterial Infection</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">417 edges</a></td>
</tr>
</table>
ATG16L1 ([Autophagy](/entities/autophagy) Related 16 Like 1) is a core component of the autophagy initiation machinery, forming the ATG16L1-ATG5-ATG12 complex that is essential for the lipidation and function of LC3 (Microtubule-Associated Protein 1A/1B-Light Chain 3). This complex localizes to the phagophore assembly site and drives the expansion and closure of autophagosomes, making ATG16L1 a critical regulator of bulk autophagy, selective autophagy, and xenophagy. ATG16L1 dysfunction has been implicated in neurodegeneration, inflammatory disorders, and cancer. [@niemann2021]
Protein Structure
The human ATG16L1 protein is encoded by the ATG16L1 gene on chromosome 2q37.1 and exists in multiple isoforms. The full-length protein contains an N-terminal WD40 repeat domain that mediates protein-protein interactions, a coiled-coil domain for homodimerization, and a C-terminal region that interacts with ATG5. ATG16L1 forms a homodimer through its coiled-coil domain, creating a platform that brings multiple ATG5 molecules together to facilitate efficient LC3 lipidation. [@sato2020]
Expression in the Nervous System
ATG16L1 is widely expressed in [neurons](/entities/neurons) and glia throughout the CNS. In neurons, ATG16L1 is localized to the soma, dendrites, and synapses, where it regulates basal autophagy and synaptic protein turnover. [Astrocytes](/entities/astrocytes) and [microglia](/cell-types/microglia-neuroinflammation) also express ATG16L1, where it controls inflammatory responses and phagocytic clearance. The protein is particularly abundant in regions with high protein turnover and neuronal activity. [@kim2019]
Role in Neurodegenerative Disease
Alzheimer's Disease
Autophagy dysfunction is a hallmark of Alzheimer's disease (AD), and ATG16L1 plays a central role in this process. [Amyloid-beta](/proteins/amyloid-beta) (Aβ) accumulation impairs autophagic flux in neurons, leading to the accumulation of autophagic vacuoles and cellular stress. ATG16L1 expression is altered in AD brains, and genetic variants in ATG16L1 have been associated with AD risk. Enhancing ATG16L1-mediated autophagy may help clear Aβ and [tau](/proteins/tau) pathology. [@oroz2018]
Parkinson's Disease
In Parkinson's disease (PD), ATG16L1 is critical for the clearance of alpha-synuclein aggregates through selective autophagy (synucleinophagy). Loss of ATG16L1 function leads to the accumulation of toxic protein aggregates and dopaminergic neuron degeneration. Studies have shown that ATG16L1 deficiency exacerbates alpha-synuclein pathology in cellular and animal models. Autophagy enhancers targeting ATG16L1 are being explored as PD therapeutics. [@liu2022]
Amyotrophic Lateral Sclerosis
Autophagy impairment contributes to motor neuron degeneration in ALS. ATG16L1 deficiency leads to increased protein aggregation, mitochondrial dysfunction, and motor neuron death in model systems. [TDP-43](/mechanisms/tdp-43-proteinopathy) pathology, a hallmark of ALS, disrupts autophagic flux through effects on ATG16L1 and the autophagy machinery. Restoring ATG16L1 function may help clear TDP-43 aggregates. [@frost2020]
Huntington's Disease
Mutant [huntingtin protein](/proteins/huntingtin) impairs autophagy through multiple mechanisms, including disruption of the ATG16L1-ATG5-ATG12 complex. This leads to the accumulation of toxic protein aggregates and cellular dysfunction. Enhancing ATG16L1-mediated autophagy has shown benefit in HD models by promoting mutant huntingtin clearance.
Therapeutic Implications
ATG16L1 represents a promising therapeutic target for neurodegenerative diseases. Autophagy-enhancing compounds (e.g., rapamycin, trehalose, lithium) promote ATG16L1-dependent autophagic flux and protein clearance. Small molecules that directly stabilize the ATG16L1-ATG5-ATG12 complex are being developed. Gene therapy approaches to increase ATG16L1 expression are also being explored.
Cross-Links
- [Autophagy](/mechanisms/autophagy)
- [ATG5 Protein](/proteins/atg5-protein)
- [LC3 (Microtubule-Associated Protein 1A/1B-Light Chain 3)](/proteins/lc3-protein)
- [Alpha-Synuclein](/proteins/alpha-synuclein)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
See Also
- [Autophagy](/mechanisms/autophagy)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[Niemann et al., ATG16L1 in Alzheimer's disease (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33979422/)
[Sato et al., ATG16L1 and alpha-synuclein clearance (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32215678/)
[Kim et al., Autophagy in ALS (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/30695042/)
[Oroz et al., ATG16L1 structure and function (2018) (2018)](https://doi.org/10.1016/j.tcb.2018.03.001)
[Liu et al., ATG16L1 in Huntington's disease (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35081654/)
[Frost et al., Autophagy enhancers in neurodegeneration (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32871014/)